Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Fig. 3

Dose-dependent amelioration of arthritis symptoms following treatment with dasatinib. Clinical (a), histopathological (b), as well as individual histopathological arthritis (c) scores depicting the dose-dependent response of Tg197 animals to dasatinib treatment. (* p-value < 0.05; ** p-value < 0.01; *** p-value ≤ 0.0001). All data are shown as mean ± SEM and all comparisons were made against vehicle

Back to article page